All In Biotech

Drug Trial Radar · NCT03794076

Cromoglicate Adjunctive Therapy for Outpatients With Schizophrenia

Cromoglicte Adjunctive Therapy for Outpatients With Schizophrenia

Last checked: Nov 20, 2026Latest source record: Mar 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 160 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

160

Planned (sponsor's estimate)

Start

Apr 1, 2019

Primary completion

Jan 2028

Study completion Jun 2028

Sponsor

Lead sponsor
Vishwajit Nimgaonkar, MD PhDAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Stanley Medical Research Institute
First posted
Jan 4, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a double blind adjunctive randomized controlled trial for schizophrenia using cromoglicate.

Conditions

  • Schizophrenia
  • Schizo Affective Disorder

Interventions

  • CromoglycateDrug

    Cromoglycate will be administered intranasally (nasal spray) (1 spray each nostril 4 times a day, 5.2 mg/spray

  • PlaceboDrug

    Normal saline nasal spray will be administered intranasally (nasal spray) (1 spray each nostril 4 times a day, 5.2 mg/spray)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Improvement in positive symptomsTime frame: 12 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Pittsburgh

    Pittsburgh, Pennsylvania · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.